Skip to Content

Core Laboratories Inc

CLB: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$44.00StqDtxqstmpd

Solid Fourth Quarter for Core Laboratories Driven by Steadily Climbing Production Activity Worldwide

Wide-moat Core Laboratories concluded the year on sound footing. Results for fiscal 2022 fell in line with our expectations, with total revenue increasing 4% year over year and operating margins slightly contracting to 8% from 10% in 2021. We’ll incorporate the firm’s full financial and operating results shortly, but based on our initial review, our $29 per share fair value estimate is unchanged.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CLB so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center